MyD88/CD40 signaling retains CAR T cells in a less differentiated state

Chimeric antigen receptor (CAR) T cell therapy for solid tumors has shown limited efficacy in early-phase clinical studies. The majority of CARs encode CD28 and/or 41BB costimulatory endodomains, and we explored whether MyD88 and CD40 (MC) costimulatory endodomains in CARs could improve their antitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Prinzing, Brooke, Schreiner, Patrick, Bell, Matthew, Fan, Yiping, Krenciute, Giedre, Gottschalk, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710311/
https://www.ncbi.nlm.nih.gov/pubmed/33148882
http://dx.doi.org/10.1172/jci.insight.136093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710311/
https://www.ncbi.nlm.nih.gov/pubmed/33148882
http://dx.doi.org/10.1172/jci.insight.136093

Ejemplares similares